GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tevogen Bio Holdings TVGN · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.84

+4.47%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tevogen Bio Holdings

From its filings with the US Securities and Exchange Commission

SEC filings

Tevogen Bio Holdings is based in Warren, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TVGN. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $26.3m. At that date it held total assets of $4.4m and shareholders' equity of −$8.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
4 Nov 2021
Head office
15 INDEPENDENCE BOULEVARD, SUITE #210, WARREN, NJ, 07059
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Surendra AjjarapuChairman of the Board, Chief Executive Officer
  • Mr. Francis KnuettelChief Financial Officer
  • Mr. Donald FellIndependent Director
  • Mr. Michael PetersonIndependent Director
  • Mr. Scott SussmanIndependent Director
  • Mr. Avinash WadhwaniIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
34
Environment
32
Social
64
Governance
5
Carbon reduction policy
No
Human rights policy
No

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company in the US.
  • The firm harnesses CD8+ cytotoxic T lymphocytes to develop off-the-shelf precision T cell therapies.
  • TVGN 489 targets infectious diseases and neurological disorders for immunocompromised and high-risk elderly patients.

Weaknesses

  • TVGN 489 is still in development and has not yet received regulatory approval.
  • TVGN 601 and TVGN 930 are in early-stage development with no commercial products yet.
  • The company went public in November 2021 and may face pressure to demonstrate progress.

Opportunities

  • TVGN 489 addresses unmet needs for Long COVID treatment and prevention strategies.
  • TVGN 601 offers potential therapeutic applications for patients suffering from multiple sclerosis.
  • TVGN 930 targets EBV-associated lymphomas, filling a critical gap in oncology treatments.

Threats

  • Competitors in the biotechnology industry may develop superior off-the-shelf T cell therapies.
  • Regulatory hurdles could delay the approval of TVGN 489 for infectious disease treatment.
  • Clinical trial failures for TVGN 601 or TVGN 930 could hinder future revenue streams.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.